Bao Do

Publication Details

  • Analysis of FAS (CD95) gene mutations in higher-grade transformation of follicle center lymphoma LEUKEMIA & LYMPHOMA Do, B., Lossos, I. S., Thorstenson, Y., Oefner, P. J., Levy, R. 2003; 44 (8): 1317-1323

    Abstract:

    The FAS antigen (CD95/APO-1) is suggested to be a tumor suppressor gene since mice and patients with congenital FAS mutations are prone to B cell lymphomas and somatic FAS mutations are described in hematological and solid tumors. Indeed, mutations of the FAS antigen have been found in 13% of multiple myelomas, 6% of follicle center lymphomas (FCL) and 21% of diffuse large B-cell lymphomas (DLBCL). To assess the possible role of FAS mutations in higher-grade transformation of FCL, biopsy specimens from 16 FCL patients were analyzed by denaturing high performance liquid chromatography and direct sequencing. Overall, 17 biopsy specimens obtained at the time of FCL diagnosis (2 biopsy specimens from one patient), 4 sequential biopsies obtained at the time of FCL relapse and 14 sequential biopsies from the time of morphologic transformation to DLBCL were evaluated. Ten polymorphisms were detected, only 4 of which have been reported previously. Nine of the polymorphisms occurred in non-translated regions, while one silent mutation was located in exon 7. Neither loss of heterozygosity nor occurrence of new mutations was observed upon higher-grade transformation of FCL to DLBCL.

    View details for DOI 10.1080/1042819031000090228

    View details for Web of Science ID 000183421700007

    View details for PubMedID 12952224

Stanford Medicine Resources:

Footer Links: